全文获取类型
收费全文 | 1047篇 |
免费 | 74篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 19篇 |
妇产科学 | 10篇 |
基础医学 | 132篇 |
口腔科学 | 19篇 |
临床医学 | 60篇 |
内科学 | 333篇 |
皮肤病学 | 11篇 |
神经病学 | 44篇 |
特种医学 | 32篇 |
外科学 | 90篇 |
综合类 | 4篇 |
预防医学 | 88篇 |
眼科学 | 129篇 |
药学 | 65篇 |
中国医学 | 5篇 |
肿瘤学 | 78篇 |
出版年
2021年 | 14篇 |
2020年 | 7篇 |
2019年 | 12篇 |
2018年 | 11篇 |
2017年 | 11篇 |
2016年 | 17篇 |
2015年 | 14篇 |
2014年 | 14篇 |
2013年 | 28篇 |
2012年 | 37篇 |
2011年 | 49篇 |
2010年 | 24篇 |
2009年 | 21篇 |
2008年 | 55篇 |
2007年 | 62篇 |
2006年 | 74篇 |
2005年 | 53篇 |
2004年 | 53篇 |
2003年 | 49篇 |
2002年 | 55篇 |
2001年 | 46篇 |
2000年 | 46篇 |
1999年 | 44篇 |
1998年 | 8篇 |
1997年 | 12篇 |
1996年 | 9篇 |
1995年 | 9篇 |
1994年 | 7篇 |
1993年 | 9篇 |
1992年 | 20篇 |
1991年 | 26篇 |
1990年 | 29篇 |
1989年 | 19篇 |
1988年 | 19篇 |
1987年 | 14篇 |
1986年 | 12篇 |
1985年 | 16篇 |
1984年 | 10篇 |
1983年 | 12篇 |
1982年 | 11篇 |
1979年 | 4篇 |
1975年 | 5篇 |
1974年 | 12篇 |
1973年 | 9篇 |
1972年 | 11篇 |
1971年 | 10篇 |
1970年 | 3篇 |
1969年 | 4篇 |
1968年 | 6篇 |
1967年 | 3篇 |
排序方式: 共有1123条查询结果,搜索用时 15 毫秒
1.
2.
Association of ERG and TMPRSS2‐ERG with grade,stage, and prognosis of prostate cancer is dependent on their expression levels 下载免费PDF全文
3.
Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry 总被引:1,自引:0,他引:1 下载免费PDF全文
Font E Rosario O Santana J García H Sommadossi JP Rodriguez JF 《Antimicrobial agents and chemotherapy》1999,43(12):2964-2968
4.
A multicenter validation of recombinant β3 integrin–coupled beads to detect human platelet antigen‐1 alloantibodies in 498 cases of fetomaternal alloimmune thrombocytopenia 下载免费PDF全文
Winnie Chong Ernest Turro Paul Metcalfe Rizwan Yusuf Yves Mérieux Dominique Rigal Leendert Porcelijn Elly Huiskes Geoff Lucas Nina Bendukidze Ann Green Rita Fontão‐Wendel Anne Husebekk Jonathan Dixey Alan Guest Rosey Mushens Willem H. Ouwehand Cristina V. Navarrete 《Transfusion》2015,55(11):2742-2751
5.
Rosskopf K Ragg SJ Worel N Grommé M Preijers FW Braakman E Schuurhuis GJ van Riet I Wendel S Fontão-Wendel R Lazar A Goldman M Halpenny M Giulivi A Letcher B McGann L Korhonen M Arvola A Humpe A Buwitt-Beckmann U Wiesneth M Schauwecker P Schrezenmeier H Bönig H Henschler R Seifried E Accorsi P Bonfini T Takanashi M van Beckhoven JM Brand A Gounder D Wong A Dooccey R Forrest E Galea G Smythe J Pawson R Reems JA Oh J Reesink HW Panzer S 《Vox sanguinis》2011,101(3):255-275
6.
Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide 下载免费PDF全文
Laura Ferrer‐Font Nuria Arias‐Ramos Silvia Lope‐Piedrafita Margarida Julià‐Sapé Martí Pumarola Carles Arús Ana Paula Candiota 《NMR in biomedicine》2017,30(9)
Glioblastoma (GBM) causes poor survival in patients even when applying aggressive treatment. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment, but resistance always ensues. In previous years, efforts have focused on new therapeutic regimens with conventional drugs to activate immune responses that may enhance tumor regression and prevent regrowth, for example the “metronomic” approaches. In metronomic scheduling studies, cyclophosphamide (CPA) in GL261 GBM growing subcutaneously in C57BL/6 mice was shown not only to activate antitumor CD8+ T‐cell response, but also to induce long‐term specific T‐cell tumor memory. Accordingly, we have evaluated whether metronomic CPA or TMZ administration could increase survival in orthotopic GL261 in C57BL/6 mice, an immunocompetent model. Longitudinal in vivo studies with CPA (140 mg/kg) or TMZ (range 140–240 mg/kg) metronomic administration (every 6 days) were performed in tumor‐bearing mice. Tumor evolution was monitored at 7 T with MRI (T2‐weighted, diffusion‐weighted imaging) and MRSI‐based nosological images of response to therapy. Obtained results demonstrated that both treatments resulted in increased survival (38.6 ± 21.0 days, n = 30) compared with control (19.4 ± 2.4 days, n = 18). Best results were obtained with 140 mg/kg TMZ (treated, 44.9 ± 29.0 days, n = 12, versus control, 19.3 ± 2.3 days, n = 12), achieving a longer survival rate than previous group work using three cycles of TMZ therapy at 60 mg/kg (33.9 ± 11.7 days, n = 38). Additional interesting findings were, first, clear edema appearance during chemotherapeutic treatment, second, the ability to apply the semi‐supervised source analysis previously developed in our group for non‐invasive TMZ therapy response monitoring to detect CPA‐induced response, and third, the necropsy findings in mice cured from GBM after high TMZ cumulative dosage (980–1400 mg/kg), which demonstrated lymphoma incidence. In summary, every 6 day administration schedule of TMZ or CPA improves survival in orthotopic GL261 GBM with respect to controls or non‐metronomic therapy, in partial agreement with previous work on subcutaneous GL261. 相似文献
7.
María del Mar lvarez‐Torres Javier Juan‐Albarracín Elies Fuster‐Garcia Fuensanta Bellvís‐Bataller David Lorente Gaspar Reyns Jaime Font de Mora Fernando Aparici‐Robles Carlos Botella Jose Muoz‐Langa Raquel Faubel Sabina Asensio‐Cuesta Germn A. García‐Ferrando Eduard Chelebian Cristina Auger Jose Pineda Alex Rovira Laura Oleaga Enrique Moll‐Olmos Antonio J. Revert Luaba Tshibanda Girolamo Crisi Kyrre E. Emblem Didier Martin Paulina Due‐Tnnessen Torstein R. Meling Silvano Filice Carlos Sez Juan M. García‐Gmez 《Journal of magnetic resonance imaging : JMRI》2020,51(5):1478-1486
8.
Rosas J Ramos-Casals M Ena J García-Carrasco M Verdu J Cervera R Font J Caballero O Ingelmo M Pascual E 《Rheumatology (Oxford, England)》2002,41(6):670-675
OBJECTIVES: To examine salivary function in patients with primary Sj?gren's syndrome (SS) by assessing unstimulated and stimulated flows using 5 mg of pilocarpine in a 5% solution, in order to define their clinical usefulness in the evaluation of xerostomia in patients with primary SS as well as to identify those factors related to the increase in salivary flow after pilocarpine stimulation. METHODS: We investigated the clinical and immunological characteristics of 60 consecutive patients with primary SS. All patients fulfilled four or more of the preliminary diagnostic European criteria for SS. We measured unstimulated (basal) salivary flow (BSF) in all patients. In patients with BSF =1.5 ml, stimulated salivary flows (SSF) were also measured after stimulation with an ophthalmic 5% pilocarpine solution (0.1 ml=5 mg, administered sublingually). SSF was also measured after oral administration of 50 mg anetholetrithione (ANTT) in the same patients. These stimulated salivary flows were measured 1, 2 and 3 h after the stimulus. RESULTS: Of the 60 patients, 55 were women and five men, with a mean age at the SS onset of 61 yr (range 18-82 yr). The mean BSF for SS patients was 1.40+/-0.17 ml. Fifty (83%) patients showed a BSF less than 1.5 ml. The stimulated salivary flow after 1 h was 3.23 ml in the pilocarpine group and 0.57 in the ANTT group (P<0.001); after 2 h it was 1.32 ml in the pilocarpine group and 0.52 in the ANTT group (P=0.02) and after 3 h it was 0.80 ml in the pilocarpine group and 0.41 in the ANTT group (P=0.046). No clinical or immunological differences were found between SS patients with BSF more or less than 1.5 ml, although patients with a BSF less than 1.5 ml showed a parotid scintigraphy class III or IV more frequently (42 vs 0%, P=0.01). SS patients with a pilocarpine SSF less than 1.5 ml had a longer duration of SS (73.3 vs 31.3 months, P=0.03) and a higher prevalence of positive anti-Ro/SS-A (70 vs 36%, P=0.038), anti-La/SS-B (65 vs 32%, P=0.038), parotid scintigraphy class III-IV (79 vs 9%, P<0.001) and positive salivary gland biopsy (90 vs 43%, P<0.001). CONCLUSION: The study of xerostomia using basal and pilocarpine SSF is simple to perform, acceptable to patients and needs no special equipment. We describe a significant increase in SSF using a solution of 5% pilocarpine in comparison with salivary flow obtained after stimulation with ANTT. Twenty-two of the 46 patients with low BSF had stimulated flows over 1.5 ml. These 'responder' patients showed a shorter duration of sicca symptoms, a lower frequency of positive immunological markers and milder grades of scintigraphic patterns and lymphocytic infiltrates in salivary gland biopsies. This subset of patients probably maintain a residual capacity of their salivary glands, as opposed to the 'non-responder' patients, who had a longer duration of sicca syndrome evolution with more severe involvement of the salivary glands. 相似文献
9.
We conducted the current study to analyze the prevalence and clinical significance of circulating monoclonal immunoglobulins in patients with Sj?gren syndrome (SS), focusing on the association with extraglandular features, immunologic markers, hematologic neoplasia, and hepatitis C virus (HCV) infection. We performed serum immunoelectrophoresis in 200 patients with primary SS and 37 patients with HCV-related SS. All patients fulfilled 4 or more of the 1993 European classification criteria for SS.Of the 200 patients with primary SS, 35 (18%) presented circulating monoclonal immunoglobulins. The monoclonal bands identified were 20 IgG (13 kappa, 7 lambda), 10 IgM (5 kappa, 5 lambda), 2 IgAkappa, and 3 free circulating light chains. Of the 37 SS-HCV patients, 16 (43%) had circulating monoclonal immunoglobulins. The monoclonal bands identified were 10 IgMkappa, 5 IgGlambda, and 1 free light lambda chain. Compared with primary SS patients, SS-HCV patients presented a higher frequency of monoclonal immunoglobulins (43% vs 18%, p = 0.001), with monoclonal IgMkappa being the most frequent monoclonal band. Six (12%) of the 51 SS patients with circulating monoclonal immunoglobulins presented hematologic neoplasia, compared with 3 (1.6%) of those without monoclonal immunoglobulins (p = 0.004; odds ratio = 8.13; 95% confidence intervals, 1.64-51.54). In 2 of the 6 patients with monoclonal immunoglobulins and lymphoproliferative disorders, a change of the monoclonal component was detected in previous immunoelectrophoresis determinations before the development of hematologic neoplasia. Circulating monoclonal immunoglobulins were detected in nearly 20% of patients with primary SS, with monoclonal IgG being the most frequent type of immunoglobulin detected. In SS-HCV patients, the prevalence of monoclonal immunoglobulins was higher (43%), with monoclonal IgM being the most frequent type found. SS-HCV patients presented a more restrictive monoclonal expression (limited to either monoclonal IgMkappa or monoclonal IgGlambda) than primary SS patients, who showed all types of heavy and light chains. 相似文献
10.
A. Juliá M. Olona J. Bueno E. Revilla J. Rosselló J. Petit M. Morey A. Flores Ll. Font J. Maciá 《British journal of haematology》1991,79(3):366-371
The prognostic value of 36 clinical and analytical parameters at diagnosis in patients with drug-induced agranulocytosis was analysed in an adult population. This multicentre, retrospective study examined possible prognostic factors by multiple logistic regression analysis in a series of 168 clinical episodes. The overall mortality was 16%. Renal insufficiency at diagnosis and the development of bacteraemia were associated with a poor prognosis. Advanced age, decreased leucocyte count, lymphocytopenia, bone marrow myeloid hypoplasia, increased percentage of bone marrow plasma cells and shock were found to be associated with a poor prognosis only in the univariate analysis. An independent analysis of the myeloid cellularity at diagnosis showed an inverse correlation with the time to recovery of the granulocyte counts (r = -0.43; P = 0.001). Our data indicate that despite some important clinical differences (higher incidence of infections of the oropharynx, shorter period of neutropenia and almost exclusive presence of gram-negative organisms), the infections complicating the treatment of cancer patients have the same prognostic features than those seen in patients with acute agranulocytosis. Therefore the established therapeutic guidelines for neutropenia after cancer chemotherapeutic agents are applicable to patients with acute agranulocytosis. 相似文献